K76.7
Conditions
Interventions
Group 1: Study group (Patients with confirmed hepatorenal syndrome and indication for terlipressin therapy):
1. Study visit (inclusion): Blood and urine parameters, Doppler sonography/MVFI
2. Study vi
Sponsors
Universitätsklinikum Halle, Klinik für Innere Medizin I, Zentrum für diagnostischen und interventionellen Ultraschall
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Clinical suspicion of HRS-AKI (study group) or laboratory findings suggestive of AKI of another etiology (non-liver-AKI & non-HRS-AKI => control group) - Patient suitable for sonographic diagnostics - Written consent form - Present capacity to consent
Exclusion criteria
Exclusion criteria: - Pre-existing chronic nephropathy with structural kidney disease - Pregnancy/Breastfeeding - Malignancy of the kidneys - Hemodialysis - Administration of human albumin in the 7 days prior to study inclusion - HRS-NAKI
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A significant increase in renal vascularization detected by Doppler sonography in patients with HRS after terlipressin therapy when compared to the control group (patients with non-HRS-AKI and non-liver-AKI of other etiologies) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Higher renal vascularization on Doppler sonography (MVFI) in patients of the control group (non-HRS-AKI & non-liver-AKI) compared to patients with HRS-AKI 2. Increase in renal stiffness due to increased blood flow after therapy of HRS with vasopressors (2D shear wave elastography and strain elastography) 3. Elevated resistance index (RI) at the time of HRS diagnosis with a decrease after therapy 4. Unchanged renal vascularization in patients with acute kidney failure without liver cirrhosis | — |
Countries
Germany
Contacts
Public ContactValentin Blank
Universitätsklinikum Halle, Klinik für Innere Medizin I, Zentrum für diagnostischen und interventionellen Ultraschall
Outcome results
None listed